The Form 4 filing, an SEC report of insider stock activity, lists Martine A. Rothblatt as chairperson and CEO. The trades took place on Nov. 16, 2026. The filing followed on Nov. 17, 2026.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-16 |
| Date of Latest Transaction | 2026-11-16 |
| Buy/Sell | sell |
| Transaction Count | 15 |
| Shares Transacted | 9,500 |
| Price | $587.74 |
| Total Transaction Value | $5,583,500.99 |
| Insider | |
| Ticker Symbol | UTHR |
| Company | UNITED THERAPEUTICS Corp |
| Insider Name | ROTHBLATT MARTINE A |
| Insider Title | Chairperson & CEO |
| Sector - Industry | Healthcare - Drug Manufacturers - Specialty & Generic |
| Holdings | |
| Total Shares Owned After Transaction | 324,443 |
| Position Size Change | 2.84% |
| Filing | |
| Filing Date | 2026-11-17 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a sale of United Therapeutics (UTHR) shares, reported with transaction code S. The reported activity includes 15 sales by one insider.
What was the average price of the transaction?
The average sale price was $587.74 per share across the 15 transactions. Prices for each individual sale were not provided.
How did this transaction affect the insider's holdings?
Martine A. Rothblatt sold 9,500 shares and reported 324,443 shares owned afterward. The shares sold made up 2.84% of the reported shares held before the sales.
What's the total transaction value?
The total value was $5,583,500.99. It covers all 9,500 shares sold across the 15 reported transactions.
Are there any special circumstances around this transaction?
The available information identifies a Rule 10b5-1 plan reference. Such plans set trading instructions in advance. The filing's footnote text was not provided. It is unclear which of the 15 sales the plan reference covers. The plan's terms and start date are unknown. A plan reference alone does not show whether the trades met the rule's legal requirements.
For research purposes only; not investment advice.